Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/531"

PredicateValue (sorted: default)
rdfs:label
rdf:type
?:Evidence_enzyme_system
?:Evidence_numb_subjects
?:Evidence_object_dose
?:Evidence_precip_dose
?:Evidence_type
?:Evidence_value
?:content
"route of admininistration: oral study duration: 6 days population: 16 healthy subjects (8 male, 8 female) from the UK; 15 Caucasian, 1 of African ancestry tested for known CYP450 polymorphisms? Yes -- CYP2D6 and CYP2C19 genotyping -- 1 CYP2D6 poor metabolizer ages: 18-45 description: SUBJECTS: 16 healthy subjects (18-45 years; eight male and eight female (15 Caucasian and one black subject) in the omeprazole study were recruited in the UK. CYP2D6 and CYP2C19 [genotyping] were determined according to standard methods. The results were only used to aid interpretation of the pharmacokinetic results. STUDY DESIGN: Sixteen subjects were administered omeprazole (30 mg once daily) or placebo for 6 days. On the morning of day 5, a single dose of 20 mg escitalopram was administered. The wash-out period was 3 weeks between the treatments. RESULTS: Omeprazole (30 mg once daily) caused a significant increase (+51%) in the AUC(0-inf) for escitalopram given as a single 20 mg oral dose. A single CYP2D6 poor metabolizer was identified in each of the two studies. However, the results from these subjects were within the ranges of those from the other subjects."
dc:creator
dc:date
"09/15/2010 13:07:44"
rdfs:seeAlso

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl

The resource appears as object in one triple:

{ omeprazole_increases_auc_escitalopram, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1768 }

Context graph